Explorative Evaluation of the Impact of Premenstrual Disorder on Daily Functioning and Quality of Life
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objectives: To assess the effects of premenstrual disorders on health-related quality of life (HR-QOL), hobbies and social activities, and relationships with others in the multinational IMPACT study.
Methods: Women aged 15–45 years were screened for suspected premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS) and invited to participate in this web-based study. Based on the Daily Record of Severity of Problems (DRSP), prospectively assessed over two observational cycles, participants were grouped into two categories: no perceived symptoms/mild PMS or moderate-to-severe PMS/PMDD. HR-QOL was assessed retrospectively at baseline using the SF-12.
Results: Overall, 1477 women started the study. Of these, 822 (56%) completed the DRSP and SF-12 questionnaires as planned. Moderate-to-severe PMS/ PMDD was associated with a reduction in HR-QOL compared with no perceived symptoms/mild PMS for both mental component scores (34.5±8.7 vs 39.0±9.5) and physical component scores (48.9±7.9 vs 51.1±7.2). Women with moderate-to-severe PMS/PMDD experienced a significantly greater mean number of days with at least moderate interference with hobbies or social activities (5.6 vs 1.1 day; p < 0.05, t-test), and relationships with others (5.4 vs 1.1 day) than those with no perceived symptoms/mild PMS.
Conclusions: Moderate-to-severe PMS/PMDD has a negative impact on HR-QOL, hobbies and social activities, and relationships with others. Studies with a confirmatory design are needed to confirm these results.
- Premenstrual dysphoric disorder. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000: 771-4
- Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med 1999 Oct; 8(8): 1043–52 CrossRef
- Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med 2000 Sep; 9(7): 757–68 CrossRef
- Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997 Sep 24; 278(12): 983–8 CrossRef
- Barnard K, Frayne SM, Skinner KM, et al. Health status among women with menstrual symptoms. J Womens Health (Larchmt) 2003 Nov; 12(9): 911–9 CrossRef
- Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003 Jul; 48(7): 515–24
- Yang M, Wallenstein G, Hagan M, et al. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) 2008 Jan–Feb; 17(1): 113–21 CrossRef
- Heinemann LA, Do Minh T, Filonenko A, et al. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. Womens Health Issues 2010 Jan; 20(1): 58–65 CrossRef
- The American College of Obstetricians and Gynecologists. Premenstrual syndrome: clinical management guidelines for obstetricians-gynecologists. ACOG Practice Bulletin 2000; 15: 1–9
- Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006 Jan; 9(1): 41–9 CrossRef
- Ware Jr J, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 Mar; 34(3): 220–33 CrossRef
- Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005 Dec; 72(6): 414–21 CrossRef
- Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005 Sep; 106(3): 492–501 CrossRef
- Heinemann L, Damonte Khoury C, Korner P. Assessment of health-related quality of life and economic effect in patients with premenstrual disorders [abstract]. Obstet Gynecol 2008; 111(4 Suppl.): 13S
- Borenstein JE, Dean BB, Leifke E, et al. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt) 2007 Oct; 16(8): 1139–44 CrossRef
- Dean BB, Borenstein JE, Knight K, et al. Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt) 2006 Jun; 15(5): 546–55 CrossRef
- Kuczmierczyk AR, Labrum AH, Johnson CC. Perception of family and work environments in women with premenstrual syndrome. J Psychosom Res 1992 Dec; 36(8): 787–95 CrossRef
- Explorative Evaluation of the Impact of Premenstrual Disorder on Daily Functioning and Quality of Life
The Patient: Patient-Centered Outcomes Research
Volume 3, Issue 2 , pp 125-132
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors